


DOCUMENT MADE AVAILABLE UNDER THE PATENT COOPERATION TREATY (PCT)

International application number:	PCT/US2020/044771
International filing date:	03 August 2020 (03.08.2020)
Document type:	Certified copy of priority document
Document details:	Country/Office: US
	Number: 62/895,869
	Filing date: 04 September 2019 (04.09.2019)
Date of receipt at the International Bureau:	20 August 2020 (20.08.2020)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a),(b) or (b-bis)

1088742



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

August 19, 2020

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 62/895,869

FILING DATE: *September 04, 2019*

RELATED PCT APPLICATION NUMBER: *PCT/US20/44771*

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS *US62/895,869*



Certified by

Anders Ivarsson

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

PROVISIONAL APPLICATION FOR PATENT COVER SHEET – Page 1 of 2

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Priority Mail Express® Label No. _____

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
John	Wurst	Poway, CA
Additional inventors are being named on the _____ separately numbered sheets attached hereto.		
TITLE OF THE INVENTION (500 characters max):		
Methods and Compositions for the Treatment of Hair Loss		
Direct all correspondence to: CORRESPONDENCE ADDRESS ☐ The address corresponding to Customer Number:		
OR		
☒ Firm or Individual Name John E. Wurst		
Address 15454 Willow Ranch Trail		
City Poway	State CA	Zip 92064
Country USA	Telephone	Email John.wurst100@hotmail.com
ENCLOSED APPLICATION PARTS (check all that apply)		
☒ Application Data Sheet. See 37 CFR 1.76. ☐ CD(s), Number of CDs _____		
☐ Drawing(s) Number of Sheets _____ ☐ Other (specify) _____		
☒ Specification (e.g., description of the invention) Number of Pages 37		
Fees Due: Filing Fee of \$280 (\$140 for small entity) (\$70 for micro entity). If the specification and drawings exceed 100 sheets of paper, an application size fee is also due, which is \$400 (\$200 for small entity) (\$100 for micro entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).		
METHOD OF PAYMENT OF THE FILING FEE AND APPLICATION SIZE FEE FOR THIS PROVISIONAL APPLICATION FOR PATENT		
☒ Applicant asserts small entity status. See 37 CFR 1.27.		
☐ Applicant certifies micro entity status. See 37 CFR 1.29. Applicant must attach form PTO/SB/15A or Bor equivalent. 140		
☐ A check or money order made payable to the <i>Director of the United States Patent and Trademark Office</i> is enclosed to cover the filing fee and application size fee (if applicable). TOTAL FEE AMOUNT (\$)		
☐ Payment by credit card. Form PTO-2038 is attached.		
☐ The Director is hereby authorized to charge the filing fee and application size fee (if applicable) or credit any overpayment to Deposit Account Number: _____		

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 10 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

PROVISIONAL APPLICATION FOR PATENT COVER SHEET – Page 2 of 2

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government. (NOTE: Providing this information on a provisional cover sheet, such as this Provisional Application for Patent Cover Sheet (Form PTO/SB/16), does not satisfy the requirement of 35 U.S.C. 202(c)(6), which requires that the *specification* contain a statement specifying that the invention was made with Government support and that the Government has certain rights in the invention.)



No.



Yes, the invention was made by an agency of the U.S. Government. The U.S. Government agency name is:



Yes, the invention was made under a contract with an agency of the U.S. Government.

The contract number is: _____

The U.S. Government agency name is: _____


In accordance with 35 U.S.C. 202(c)(6) and 37 CFR 401.14(f)(4), the specifications of any United States patent applications and any patent issuing thereon covering the invention, including the enclosed provisional application, must state the following:

“This invention was made with government support under [IDENTIFY THE CONTRACT] awarded by [IDENTIFY THE FEDERAL AGENCY]. The government has certain rights in the invention.”

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

SIGNATURE



John E. Wurst

DATE

9/4/2019

TYPED OR PRINTED NAME

REGISTRATION NO.

(if appropriate)

WT-PROV-03

TELEPHONE

DOCKET NUMBER

Electronic Acknowledgement Receipt

EFS ID:	37067733
Application Number:	62895869
International Application Number:	
Confirmation Number:	8711
Title of Invention:	Methods and Compositions for the Treatment of Hair Loss
First Named Inventor/Applicant Name:	John Edward Wurst
Correspondence Address:	John Wurst - 15454 Willow Ranch Trail - Poway CA 92064 US 8582314452 john.wurst100@hotmail.com
Filer:	John Wurst
Filer Authorized By:	
Attorney Docket Number:	WT-PROV3
Receipt Date:	04-SEP-2019
Filing Date:	
Time Stamp:	18:20:00
Application Type:	Provisional

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Provisional Cover Sheet (SB16)	scan0123.pdf	104192	no	2
			51392559bd5705a855ea5f99c1ab482ff8319185		
Warnings:					
This is not a USPTO supplied Provisional Cover Sheet SB16 form.					
Information:					
2	Specification	HairGrowthProv2.pdf	653766	no	38
			2e9f553f9b1db49bcb46a4dd84b736330ed18b490		
Warnings:					
Information:					
Total Files Size (in bytes):			757958		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

Methods and Compositions for the Treatment of Hair Loss

1. Field of the Invention

5

The present invention is directed to the use of certain prostaglandin analogues and cyclosporine, used in combination, to prevent hair loss and/or grow hair. The present invention is also directed to formulations containing prostaglandin analogues and cyclosporine to grow hair or prevent hair loss on the scalp and other areas of the body. The present invention is also
10 directed to formulations and methods for treating certain hair loss disorders such as alopecia areata.

2. Summary of the Invention

15

The Summary of Invention includes the following embodiments:

1. A composition for use in the treatment of hair loss comprising about 0.05% – 0.1% w/w latanoprost or latanoprost acid and 0.05% - 0.1% cyclosporine A and 5.0% – 15.0% w/w diethylene glycol monoethyl ether.
- 20 2. The composition of embodiment 1 wherein the composition has about 0.05% w/w latanoprost or latanoprost acid and about 0.06% w/w cyclosporine A and about 10% w/w diethylene glycol monoethyl ether.
3. The composition of embodiment 2 further comprising oleyl alcohol.
4. The composition further comprising polyethylene glycol.
- 25 5. A composition for use in growing hair on a patient that experiencing hair loss comprising about 0.05% – 0.1% w/w latanoprost or latanoprost acid and 0.05% - 0.1% w/w cyclosporine A and 5.0% – 15.0% w/w CAPTEX 300 EP/NF.
6. The composition of embodiment 5 wherein composition comprises 0.06% w/w lanaoprost or latanoprost acid and 0.08% w/w cyclosporine A.
- 30 7. The composition of embodiment 6 further comprising 10% w/w CAPTEX 300 EP/NF.

8. A composition for use in treating hair loss comprising about 0.05% – 0.1% w/w travoprost or travoprost acid and 0.05% - 0.1% w/w cyclosporine A.
9. The composition according to embodiment 8 further comprising one selected from the group consisting of diethylene glycol monoethyl ether, CAPTEX 300 EP/NF and polyethylene glycol.
10. The composition according to embodiments 1, 5 and 9 further comprising oleic acid.
11. A method of preventing hair loss on a patient comprising administering a formulation according to one of embodiments 1, 5 and 9 to a patient in need thereof.
12. The method of embodiment 11 wherein the formulation is applied once a day.
13. The method of embodiment 11 wherein the formulation is applied twice a day.
14. A method for causing hair growth in a patient suffering from hair loss comprising administering a formulation according to one of embodiments 1, 5 and 9 to a patient in need thereof.
15. The method of embodiment 14 wherein the patient experiences hair growth to a greater extent by applying the formulation of one of embodiments 1, 5 and 9 as compared to if the patient had not applied the formulation.
16. The method of embodiments 10 – 15 wherein the formulation maintains the hair in anaphase longer than if the formulation had not been applied.
17. The method of embodiment 14 wherein the patient reverses a substantial amount of hair loss.
18. The method of embodiment 14 wherein the formulation comprises 0.06% w/w latanoprost acid and 0.08% w/w cyclosporine A and a pharmaceutically acceptable solvent and a penetration enhancer.
19. The method of growing hair on a scalp of a patient wherein the formulation comprises 0.1% w/w latanoprost or latanoprost free acid and cyclosporine.
20. The method of claim 19 wherein the cyclosporine is cyclosporine A.
21. A composition for use in the treatment of hair loss comprising about 0.05% – 0.1% w/w bimatoprost and 0.05% - 0.1% cyclosporine A and 5.0% – 15.0% w/w diethylene glycol monoethyl ether.


22. A composition for use in growing hair comprising about 0.05% – 0.1% w/w bimatoprost and 0.05% - 0.1% cyclosporine A and 5.0% – 15.0% w/w diethylene glycol monoethyl ether.
- 5 23. A composition for use in the treatment of hair loss or to grow hair comprising about 0.05% – 0.1% w/w latanoprost or latanoprost acid and 1.0% - 5.0% minoxidil or minoxidil sulphate.
24. The composition of embodiment 23 wherein the composition has about 0.1% w/w latanoprost or latanoprost acid and about 5.0% w/w minoxidil and at least 5% w/w diethylene glycol monoethyl ether.
- 10 25. The composition of embodiment 23 further comprising oleyl alcohol or ethanol.
26. The composition of embodiment 23 further comprising polyethylene glycol.
27. A composition for use in the treatment of hair loss or to grow hair comprising about 0.05% – 0.1% w/w bimatoprost or bimatoprost acid and 1.0% - 5.0% minoxidil or minoxidil sulphate.
- 15 28. The composition of claim 27 wherein the composition has about 0.1% w/w latanoprost or latanoprost acid and about 5.0% w/w minoxidil and at least 5% w/w diethylene glycol monoethyl ether.
29. The composition of claim 27 further comprising oleyl alcohol or ethanol.
30. The composition of claim 27 further comprising polyethylene glycol.
- 20 31. A composition for use in the treatment of hair loss or to grow hair comprising about 0.05% – 0.1% w/w travoprost or travoprost free acid and 1.0% - 5.0% minoxidil or minoxidil sulphate.
32. The composition of claim 31 wherein the composition has about 0.1% w/w travoprost or travoprost free acid and about 5.0% w/w minoxidil and at least 5% w/w diethylene glycol monoethyl ether.
- 25

3. Detailed Description of the Invention

Prostaglandin analogues of the present invention include latanoprost, bimatoprost, travoprost, uenoprost, the free acids of those compounds and other known prostaglandin analogues known in the literature.

5


Latanoprost has the following structure:



10

Latanoprost is a prostaglandin analogue and is in fact a prodrug with its acid form (Latanoprost acid) being biologically active:

15




Latanoprost is an isopropyl ester, and is a prodrug which converts to latanoprost free acid by endogenous esterase enzymes. The free acid form is 200 times more potent than latanoprost as an FP receptor ligand for the human recombinant FP receptor. Latanoprost free acid is a potent FP receptor agonist with an EC₅₀ of 3.6 nM for human FP receptors, which is twice the potency of PGF_{2α}. The efficacy of PG analog esters for the treatment of glaucoma or elevated IOP correlates closely with the FP receptor binding affinity of the free acid.

Latanoprost and latanoprost acid may be present in the formulations of the present invention in the following concentrations: 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.3%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%, 0.4%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 6.0%, 7.0%, 8.0%, 9.0%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% and 25 % w/w.


Latanoprost and latanoprost acid may be present in the formulations of the present invention alone or in combination with other prostaglandin analogs.

Travoprost is a synthetic prostaglandin F analogue and isopropyl ester of the biologically active free acid. Its chemical name is [1R [1α(Z),2β(1E,3R*),3α,5α]]-7-[3,5-Dihydroxy-2-[3-hydroxy-4-[3 (trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid, 1-methylethylester. It has a molecular formula of C₂₆H₃₅F₃O₆ and a molecular weight of 500.55



Travoprost free acid has the following structure:

5



10


Travoprost and travoprost free acid may be present in the formulations of the present invention in the following concentrations: 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.3%, 0.31%, 0.32%, 0.33%,

15


0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%, 0.4%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%,
0.46%, 0.47%, 0.48%, 0.49%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%,
0.95%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%,
2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%,
5 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 6.0%, 7.0 %,
8.0 %, 9.0 %, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%,
24% and 25 % w/w.

10 Travoprost and travoprost free acid may be present in the formulations of the present
invention alone or in combination with other prostaglandin analogs or other hair growth
compounds.

15 Unoprostone isopropyl ester has the following structure:




20 Uenoprostone isopropyl ester is a prodrug which converts to uenoprostone free acid
which has the following structure:



Utenoprost isopropyl ester and utenoprost free acid while efficacious at lowering intraocular pressure, have been shown to cause no hair growth and in fact may inhibit hair growth (McCarey B. E., Kapik B. M., Kane F. E. [2004]). Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with utenoprost isopropyl 0.15%. Ophthalmology 111, 1480–1488). This demonstrates that unpredictability of prostaglandin analogs for use in growing hair.

10

Bimatoprost and other compounds may be represented generally by the formula I:




15 wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A is an alkylene or alkenylene radical having from two to six carbon atoms, which radical may be interrupted by one or more oxide radicals and substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups wherein said alkyl radical comprises from one to six carbon atoms; B is a cycloalkyl radical having from three to seven carbon atoms, or an aryl

radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals having from four to ten carbon atoms wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms; X is a radical selected from the group consisting of $-OR^4$ and $-N(R^4)_2$ wherein R^4 is independently selected from the group consisting of hydrogen, a lower


- 5 alkyl radical having from one to six carbon atoms, R^5-C- or R^5-O-C- wherein R^5 is a lower alkyl radical having from one to six carbon atoms; Z is $=O$ or represents 2 hydrogen radicals; one of R_1 and R_2 is $=O$, $-OH$ or a $-O(CO)R_6$ group, and the other one is $-OH$ or $-O(CO)R_6$, or R_1 is $=O$ and R_2 is H, wherein R_6 is a saturated or unsaturated acyclic hydrocarbon group having from 1 to about 20 carbon atoms, or $-(CH_2)_mR_7$ wherein m is 0 or an integer of from 1 to 10, and R_7
- 10 is cycloalkyl radical, having from three to seven carbon atoms, or a hydrocarbyl aryl or heteroaryl radical, as defined above, or a pharmaceutically-acceptable salt thereof, provided, however, that when B is not substituted with a pendant heteroatom-containing radical, and Z is $=O$, then X is not $-OR^4$. That is, the cycloalkyl or hydrocarbyl aryl or heteroaryl radical is not substituted with a pendant radical having an atom other than carbon or hydrogen.

- 15 Bimatoprost and other compounds may also be represented by the following general formula II:




- wherein y is 0 or 1, x is 0 or 1 and x and y are not both 1, Y is a radical selected from the group consisting of alkyl, halo, e.g. fluoro, chloro, etc., nitro, amino, thiol, hydroxy, alkyloxy, alkylcarboxy, halo substituted alkyl wherein said alkyl radical comprises from one to six carbon atoms, etc. and n is 0 or an integer of from 1 to about 3 and R_3 is $=O$, $-OH$ or $-O(CO)R_6$ wherein R_6 is as defined above. Preferably, n is 1 or 2.
- 20

Bimatoprost and other compounds may also be represented by the general formula (III).




Bimatoprost and other compounds may also be represented by the general Formula (IV):



5

Or represented by the general Formula V:



10 In all of the above formulae, as well as in those provided hereinafter, the dotted lines on bonds between carbons 5 and 6 (C-5), between carbons 13 and 14 (C-13), between carbons 8 and 12 (C-8), and between carbons 10 and 11 (C-10), indicate a single or a double bond which can be in the cis or trans configuration. If two solid lines are used that indicates a specific configuration for that double bond. Hatched lines at positions C-9, C-11 and C-15 indicate the α configuration.

15 If one were to draw the β configuration, a solid triangular line would be used.

In the compounds used in accordance with the present invention, compounds having the C-9 or C-11 or C-15 substituents in the α or β configuration are contemplated. As hereinabove

mentioned, in all formulas provided herein broken line attachments to the cyclopentane ring indicate substituents in the α configuration. Thickened solid line attachments to the cyclopentane ring indicate substituents in the α configuration. Also, the broken line attachment of the hydroxyl group or other substituent to the C-11 and C-15 carbon atoms signifies the α configuration.

5 For the purpose of this invention, unless further limited, the term "alkyl" refers to alkyl groups having from one to ten carbon atoms, the term "cycloalkyl" refers to cycloalkyl groups having from three to seven carbon atoms, the term "aryl" refers to aryl groups having from four to ten carbon atoms. The term "saturated or unsaturated acyclic hydrocarbon group" is used to refer to straight or branched chain, saturated or unsaturated hydrocarbon groups having from one to about
10 6, preferably one to about 4 carbon atoms. Such groups include alkyl, alkenyl and alkynyl groups of appropriate lengths, and preferably are alkyl, e.g. methyl, ethyl, propyl, butyl, pentyl, or hexyl, or an isomeric form thereof.

The definition of R₆ may include a cyclic component, $-(CH_2)_mR_7$, wherein n is 0 or an integer of from 1 to 10, R₇ is an aliphatic ring from about 3 to about 7 carbon atoms, or an aromatic
15 or heteroaromatic ring. The "aliphatic ring" may be saturated or unsaturated, and preferably is a saturated ring having 3-7 carbon atoms, inclusive. As an aromatic ring, R₇ preferably is phenyl, and the heteroaromatic rings have oxygen, nitrogen or sulfur as a heteroatom, i.e. R₇ may be thienyl, furanyl, pyridyl, etc. Preferably m is 0 or an integer of from 1 to 4.


Z is =O or represents two hydrogen atoms.

20 X may be selected from the group consisting of $-OR^4$ and $-N(R^4)_2$ wherein R⁴ is independently selected from the group consisting of hydrogen, a lower alkyl radical having from one to six


25 carbon atoms, $R^5 - \overset{\overset{O}{\parallel}}{C} -$ or $R^5 - O - \overset{\overset{O}{\parallel}}{C} -$ wherein R⁵ is a lower alkyl radical having from one to six carbon atoms.

Bimatoprost may also be represented by the following formula:


30



Bimatoprost is not a prodrug and is not converted into another compound or only small amounts are believed converted into bimatoprost free acid. Bimatoprost differs from the other
 5 compounds in that it is an amide:



While there is a bimatoprost free acid:



Bimatoprost is believed to exert its biological activity as a hair growth agent as an ethyl
 5 amide and not as a free acid.

Bimatoprost and bimatoprost free acid may be present in the following concentrations:
 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, .0.01%, 0.02%,
 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, %, 0.11%. 0.12%. 0.13%, 0.14%,
 0.15%; 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%,
 10 0.27%, 0.28%, 0.29%, 0.3%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%,
 0.39%, 0.4%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.5%, 0.55%,
 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%,
 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%,
 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%,
 15 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 6.0%, 7.0 %, 8.0 %, 9.0 %, 10%, 11%, 12%, 13%, 14%,
 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% and 25 % w/w.

Bimatoprost and bimatoprost free acid may be present in the formulations of the present
 invention alone or in combination with other prostaglandin analogs.

Cyclosporine occurs naturally and was isolated from the fungus *Tolypocladium inflatum*
 in 1971. Cyclosporine is an immunosuppressant and is used in Crohn's disease, nephrotic


syndrome, rheumatoid arthritis, in organ transplants to prevent rejection and dry eye disease. Cyclosporines are a group of nonpolar cyclic oligopeptides with known immunosuppressant activity. Cyclosporine A, along with several other minor metabolites, as well as cyclosporine B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y and Z, have been identified. In addition, derivatives, salts and the like of such cyclosporines and a number of synthetic analogs have been prepared and may be useful in the present invention. The use of cyclosporine A and cyclosporine A derivatives to treat various ophthalmic conditions, has been the subject of various patents, for example US Patent Nos. 5,474,979; 6,254,860; 6,350,442; and 7,368,436, the disclosure of each of which are incorporated by reference in their entireties .

In general, commercially available cyclosporines may contain a mixture of several individual cyclosporines which all share a cyclic peptide structure consisting of eleven amino acid residues with a total molecular weight of about 1,200 Dalton, but with different substituents or configurations of some of the amino acids. Thus the present invention also contemplates mixtures of different types of cyclosporine or cyclosporine components. The term "cyclosporine component" as used herein is intended to include any individual member of the cyclosporine group, salts thereof, derivatives thereof, analogs thereof and mixtures thereof, as well as mixtures of two or more individual cyclosporines salts thereof, derivatives thereof, analogs thereof and mixtures thereof.

Particularly preferred cyclosporine components include, without limitation, cyclosporine A, derivatives of cyclosporine A, salts of cyclosporine A and the like and mixtures thereof. Cyclosporine A is an especially useful cyclosporine component.

The chemical structure for cyclosporine A is represented by Formula 1:


Formula I




10 As used herein, the term “derivatives” of a cyclosporine refer to compounds having structures sufficiently similar to the cyclosporine so as to function in a manner substantially similar to or substantially identical to the cyclosporine, for example, cyclosporine A, in the present compositions and methods. Included, without limitation, within the useful cyclosporine A derivatives are those selected from ((R)-methylthio-Sar)³-(4'-hydroxy-MeLeu) cyclosporine A,
 15 ((R)-(Cyclo)alkylthio-Sar)³-(4'-hydroxy-MeLeu)⁴-cyclosporine A, and ((R)-(Cyclo)alkylthio-Sar)³-cyclosporine A derivatives described below.

5

(11)



(III)




wherein Me is methyl; Alk is 2-6C alkylene or 3-6C cycloalkylene; R is OH, COOH, alkoxy carbonyl, -NR₁R₂ or N(R₃)—(CH₂)—NR₁R₂; wherein R₁,R₂ is H, alkyl, 3-6C cycloalkyl, phenyl (optionally substituted by halo, alkoxy, alkoxy carbonyl, amino, alkylamino or dialkylamino), benzyl or saturated or unsaturated heterocyclyl having 5 or 6 members and 1-3 heteroatoms; or NR₁R₂ is a 5 or 6 membered heterocycle which may contain a further N, O or S heteroatom and may be alkylated; R₃ is H or alkyl and n is 2-4; and the alkyl moieties contain 1-4C.

The present compositions and methods may be practiced employing any suitable compositions or combinations of compositions including therapeutically effective amounts of cyclosporine component in conjunction with bimatoprost useful to promote hair growth. The cyclosporine component is present in an amount and/or concentration effective enough to provide the desired therapeutic effect when the cyclosporine-containing composition is administered to a human or animal in accordance with the present invention. Mixtures of cyclosporine components are contemplated. In one embodiment of the invention, the cyclosporine component advantageously is present in the compositions in amounts ranging from about 0.01-0.05% w/v, 0.05 – 0.1% w/v, 0.1% to about 0.5% w/v, 0.5% - 5% w/v, 5% - 15% w/v, and 15% or about 20% or 25% w/v of the composition.

In another embodiment, the cyclosporine component is present in an amount of about 0.01% to about 5% or about 10% or about 15% by weight of the composition. Cyclosporine may be present in the following concentrations: 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, %, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.3%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%, 0.4%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 6.0%, 7.0 %, 8.0 %, 9.0 %, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% and 25 % w/w.


Minoxidil:



5

Minoxidil is believed to open potassium channels and vasodilates blood vessels allowing more nutrients, blood and oxygen into the follicles. There is some evidence that minoxidil may cause hair in the telogen phase to shed, which are replaced by newer and thicker hairs in the anagen phase. Minoxidil is a prodrug which converts to minoxidil sulphate by the sulfotransferase enzyme SULT1A1.

10



Minoxidil can be combined with bimatoprost, latanoprost or travoprost which in theory
 5 causes entry into anaphase more quickly and lengthens anaphase. Minoxidil can be present in the
 following concentrations: 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%,
 0.009%, .0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, %, 0.11%,
 0.12%, 0.13%, 0.14%, 0.15%; 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%,
 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.3%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%,
 10 0.36%, 0.37%, 0.38%, 0.39%, 0.4%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%,
 0.48%, 0.49%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%,
 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%,
 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%,
 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 6.0%, 7.0 %, 8.0 %, 9.0 %, 10%,
 15 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% and 25 %
 w/w.

Bimatoprost, latanoprost and travoprost can be in combination with minoxidil at the following concentrations: 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%; 0.16%, 0.17%, 0.18%, 0.19%, 0.2%, 0.21%, 0.22%, 0.23%, 0.24%, 0.25%, 0.26%, 0.27%, 0.28%, 0.29%, 0.3%, 0.31%, 0.32%, 0.33%, 0.34%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%, 0.4%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 6.0%, 7.0 %, 8.0 %, 9.0 %, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% and 25 % w/w.

Hair growth is generally divided into three phases:

- 1) Anagen – active hair growth which last two to six years;
- 2) Catagen – transition growth which lasts two to three weeks;
- 3) Telogen – resting phase which lasts two to three months and at the end of the growth phase where the hair is shed and the cycle repeats.

Definitions

An “effective amount” of a compound is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease. Where recited in reference to a disease treatment, an “effective amount” may also be referred to as a “therapeutically effective amount.” A “reduction” of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) a disease, disorder or condition, or reducing

the likelihood of the onset (or reoccurrence) of a disease, disorder or condition or symptoms thereof. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations.

5 “Growing hair” refers to causing hair growth to increase as compared to the rate of hair growth without applying the drugs and/or formulations of the present invention.

 “Hair loss” may refer to alopecia areata, androgenetic alopecia, male pattern hair loss, female pattern hair loss, telogen effluvium, anagen effluvium, tinea capitis, cicatricial alopecia, lichen planopilaris, discoid lupus erythematosus, folliculitis decalvans, dissecting cellulitis of the
10 scalp, central centrifugal cicatricial alopecia, frontal fibrosing alopecia, loose anagen syndrome, hair shaft abnormalities, involutional alopecia, androgenic alopecia, trichotillomania, hair loss due to chemotherapy, hair loss due to infectious agents, trichorrhexis nodosa and senescent alopecia.

 A "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient"
15 means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use. "A pharmaceutically acceptable carrier/excipient" as used in the specification and claims includes both one and more than one such excipient.

20 “Preventing hair loss” means slowing down or preventing hair loss that would occur as compared to if the formulation was not applied.

 The term “prodrug” is used according to its plain ordinary meaning and is intended to mean compounds that require a chemical or enzymatic transformation in order to release the active parent drug *in vivo* prior to producing a pharmacological effect.

25 The term “soluble” refers the ability of the solvent to dissolve an amount of the active pharmaceutical ingredient that is relevant for its pharmacological effect.

 The terms "solvent" and "solvent system" define one component of the formulation, the liquid or semi-solid phase that contains the API.

The terms "stable" and "stability" are used here in relation to the shelf-life of a pharmaceutical product, and are related to the physical change, degradation or chemical decomposition of active pharmaceutical ingredients, which limits the shelf-life of a product.

5 The terms "treat" "treating" or "treatment" refers to any indicia of success in the treatment or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on
10 objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or computerized imaging systems. For example, the certain methods presented herein successfully treat acne by decreasing the incidence of acne, in inhibiting its symptoms and or cause.

The term "topical" in the context of methods described herein relates in the customary
15 sense to the administration of a compound or pharmaceutical composition which is incorporated into a suitable pharmaceutical carrier and administered at a topical treatment site of a subject. Accordingly, the term "topical pharmaceutical composition" includes those pharmaceutical forms in which the compound is administered externally by direct contact with a topical treatment site, e.g., the skin. The term "topical epidermal pharmaceutical composition" refers to
20 a pharmaceutical composition suitable for administering directed to the epidermal layer of the skin, e.g., the palpebra, the supercilium, the face, or the body. The term "topically administering" refers to administering externally by direct contact with a topical treatment site. The term "topical epidermal administering" refers to administering externally by direct contact with the epidermis.

25 Orifices of hair follicles occupy only about 0.1% of the total skin surface area of humans, while hair follicles can occupy as much as 10% of the total surface area on the human scalp (Schaefer, H., et. al. (1990) "Follicular penetration" (pgs. 163 – 173)(1990). In general, follicular openings lead to epithelial surfaces that do not have the protective stratum corneum of surface skin. Consequently, hair follicles and sebaceous glands contribute significantly to transdermal
30 drug delivery. Consequently, hydrophilic drugs can penetrate with high flux and usually through

the intrafollicular routes, along the junction of the internal and external root sheath, and rapid diffusion into the dermis by the outer root sheath. Longer lag times for the scalp skin penetration of hydrophilic drugs, as compared to the shorter time for lipophilic drugs, suggest that the permeation of hydrophilic drugs via the upper dermis is a rate-limiting step. The penetration routes of lipophilic drugs is probably along the junction of internal and external root sheath. Release of sebum by sebaceous glands associated with the hair follicle forms a lipoidal pathway for lipophilic materials in the follicles (Ebling et al., 1991). It is also believed that a penetration route for lipophilic permeants is the trans epidermal pathway. Thus, the penetration through the stratum corneum of scalp skin was also an important pathway but some drugs may use the trans follicular route. Sebum located in the follicles also plays an important role in drug penetration in the outer root sheath. Human hair follicles can vary in diameter from 5 μm to 80 μm , which can affect trans-follicular penetration. Certain penetration enhancers and solvents help fluidize lipids, in intercellular channels of the stratum corneum. Penetration of permeants and drugs through the scalp skin, is believed to be related to the rapid permeation into the hair follicles and the rapid diffusion through the outer root sheath, into the dermis, whereas the trans epidermal permeation of drugs is largely through was via the microchannels. Hydrophilic drugs also rapidly diffused into the dermis via the outer root sheath, but permeation of hydrophilic drugs via the upper dermis may be rate-limiting step and relatively slow. Human scalp anagen hair follicles are believed to express the genes and protein for three prostanoid receptors in the dermal papillae and the CTS surrounding the hair bulb, but not in the epithelial keratinocytes or the melanocytes of the hair bulb. One theory is that prostaglandin analogues binding to specific receptors on the plasma membrane of cells in the regulatory dermal papilla in the hair bulb, which probably stimulates intracellular signaling pathways, resulting in hair growth and the lessening of hair loss.

Vehicles

Table 1 lists solvents and penetration enhancers:

Capmul 808G EP/NF	Glyceryl Monocaprylate	26402-26-6
Capmul GDB EP/NF*	Glyceryl Dibehenate	94201-62-4
Capmul GMO-50 EP/NF	Glyceryl Monooleate	25496-72-4
Capmul MCM C8 EP/NF	Glyceryl Monocaprylate	26402-26-6
Capmul MCM EP/NF	Glyceryl Caprylate/Caprate	91744-32-0, or
		26402-22-2, and
		26402-26-6
Capmul INJ MCM EP/NF	Glyceryl Caprylate/Caprate	91744-32-0, or 26402-22-2 and 26402-26-6
CAPMUL INJ MCM EP	Glyceryl Caprylate/Caprate	91744-32-0, or 26402-22-2, and 26402-26-6
Capmul PG-2L EP/NF	Propylene Glycol Dilaurate	22788-19-8
Capmul PG-8 NF	Propylene Glycol Monocaprylate	68332-79-6, or 31565-12-5
Capmul PG-8-70 NF	Propylene Glycol Monocaprylate, NF Type 1	68332-79-6
Capmul PG-12 EP/NF	Propylene Glycol Monolaurate	27194-74-7
CAPTEX [®] 170 EP	Coco-Caprylate/Caprate	95912-86-0
CAPTEX 200P	Propylene Glycol Dicaprylocaprate	68583-51-7
CAPTEX 300 EP/NF	Glyceryl Tricaprylate/Tricaprate	65381-09-1
CAPTEX INJ 300 LOW C6 EP/NF/JPE	Glyceryl Tricaprylate/Tricaprate	65381-09-1, or 73398-61-5
CAPTEX 355 EP/NF/JPE	Glyceryl Tricaprylate/Tricaprate	65381-09-1, or 73398-61-5

CAPTEX INJ 355 EP/NF/JPE	Glyceryl Tricaprylate/Tricaprate	65381-09-1, or 73398-61-5
CAPTEX 8000	Glyceryl Tricaprylate, Tricaprylin	538-23-8
CAPTEX INJ 8000 NP	Glyceryl Tricaprylate, Tricaprylin	538-23-8
Captex 100	Propylene Glycol Dicaprate	53824-77-4
Captex 170	Caprylic/Capric Acid Ester of Saturated Fatty Alcohol C12-C18	95912-86-0
Captex GTO	Triolein	122-32-7
Captex NPGC	Decanoic acid, mixed esters with neopentyl glycol and octanoic acid	
CAPTEX INJ 300 LOW C6 EP/NF/JPE	Glyceryl Tricaprylate/Tricaprate	65381-09-1, or 73398-61-5
CAPTEX INJ 355 EP/NF/JPE	Glyceryl Tricaprylate/Tricaprate	65381-09-1, or 73398-61-5
CAPTEX INJ 8000 NP	Glyceryl Tricaprylate, Tricaprylin	538-23-8
Capmul INJ MCM EP*	Caprylic capric mono- & diglycerides	91744-32-0, or 26402-22-2, and 26402-26-6
Acconon INJ MC8-2 EP/NF*	PEG-8 caprylic/capric glycerides	91744-32-0, 223129-75-7
CremerCOOR® MCT 60-40	Caprylic / Capric Triglyceride	65381-09-1
CremerCOOR® MCT 70-30	Caprylic / Capric Triglyceride	65381-09-1
CremerCOOR® EHC	2-Ethylhexyl Cocoate	92044-87-6
CremerCOOR® EHL	2-Ethylhexyl Laurate	20292-08-4
CremerCOOR® EHP	2-Ethylhexyl Palmitate	29806-73-3
CremerCOOR® EHS	2-Ethylhexyl Stearate	91031-48-0

CremerCOOR® GMS 40 / SE (self-emulsifier)	Glycerol stearate	67701-33-1
CremerCOOR® IPM	Isopropyl Myristate	110-27-0
CremerCOOR® IPP	Isopropyl Palmitate	142-91-6
CremerCOOR® Triacetin	Glycerol Triacetate	102-76-1
	1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE	18194246
	DIISOPROPANOLAMINE	110974
	DIISOPROPYL ADIPATE	6938949
	DIPROPYLENE GLYCOL	25265718
	FATTY ACID ESTERS (Medium and short chain)	
	MYRISTYL ALCOHOL	112721
	N,N-DIMETHYLACETAMIDE	127195
	POLYOXYL 35 CASTOR OIL	61791126
	POLYOXYL 40 STEARATE	9004993
	POLYOXYL 40 HYDROGENATED CASTOR OIL	61788850

The solvents and penetration enhancers may be present in the following concentrations: .0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 6.0%, 7.0 %, 8.0 %, 9.0 %, 10% w/w, 11%,

12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25 %, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% w/w of the formulation.

Carbomer may be at a concentration of about 0.05-3.0% w/w, isopropyl myristate at a concentration of about 0.1 to about 10% w/w; PEG 40 castor oil at a concentration of about 0.1 to 20% w/w; carboxymethyl cellulose from 0.1 – 5.0 % w/w ethanol about 1 to about 70% w/w; diethylene glycol monoethyl ether at a concentration of about 1.0 to about 50% w/w; polysorbate 20 at a concentration of about 0.1 to about 5.0% w/w; polysorbate 40 at a concentration of about 0.1 to about 5.0% w/w; polysorbate 60 at a concentration of about 0.1 to about 5.0% w/w; glycerin at a concentration of about 1.0 to about 30% w/w; polysorbate 80 at a concentration of about 0.1 to about 5.0% w/w; PPG-5 ceteth-20 at a concentration of about 0.1 to about 5.0% w/w; oleic acid at a concentration of about 0.1 to about 5.0% w/w; isostearyl isostearate at a concentration of about 0.1 to about 10% w/w; dipropylene glycol dimethyl ether at a concentration of about 1 to about 50% w/w; diethylene glycol at a concentration of about 1 to about 50% w/w; dipropylene glycol at a concentration of about 1 to about 50% w/w; caprylic/capric at a concentration of about 0.1 to about 10% w/w; benzyl alcohol at a concentration of about 0.1 to about 2.0% w/w; silicone at a concentration of about 0.1 to about 10% w/w; PEG 40 castor oil at a concentration of about 0.1 to 20% w/w; PEG 35 castor oil at a concentration of about 0.1 to 20% w/w; oleyl alcohol at a concentration of about 0.1 to 10% w/w; glyceryl monooleate at a concentration of about 0.1 to 10% w/w; and/or water at a concentration of about 0 to about 90% w/w.

Examples:

Example I

- 0.05% w/w latanoprost acid;
0.06% w/w cyclosporine A;
10.0% w/w diethylene glycol monoethyl ether;
5 5.0 % w/w oleyl alcohol; and,
84.9% water.

Example II

- 10 0.08% w/w latanoprost acid;
0.1% w/w cyclosporine A;
15.0% w/w diethylene glycol monoethyl ether;
5% w/w PEG;
15 6.0% w/w oleyl alcohol; and,
73.8% w/w water.

Example III

- 20 0.08% w/w latanoprost acid;
0.1% w/w cyclosporine A;
15.0% w/w diethylene glycol monoethyl ether;
5% w/w PEG;
6.0% w/w oleyl alcohol; and,
25 73.8% w/w water

Example IV

- 0.06% w/w bimatoprost;
30 0.08% w/w cyclosporine A;
10.0% w/w Glyceryl Monooleate;

5.0% w/w oleic acid;
5% w/w ethanol; and,
79.8% w/w water.

5 Example V

0.08% w/w bimatoprost;
0.1% w/w cyclosporine A;
10.0% w/w diethylene glycol monoethyl ether;
10 5.0% w/w oleic acid;
5.0% oleyl alcohol; and,
79.8% w/w water.

Example VI

15
0.08% w/w latanoprost acid;
0.08% w/w cyclosporine A;
10.0% w/w polyethylene glycol;
10.0% w/w diethylene glycol monoethyl ether;
20 5.0 % w/w oleyl alcohol; and,
74.9% water.

Example VII

25 0.05% w/w bimatoprost;
0.07% w/w cyclosporine A;
10.0% w/w oleyl alcohol;
10.0% w/w diethylene glycol monoethyl ether; and,
79.0% w/w water.

30

Example VIII

- 0.05% w/w latanoprost acid;
0.08% w/w cyclosporine A;
5.0% w/w diethylene glycol monoethyl ether;
5 10.0% w/w CAPTEX 300 EP/NF;
10.0% PEG; and,
74.87% w/w water.

Example IX

- 10 0.06% w/w uenoprostone free acid;
0.08% w/w cyclosporine A;
5.0% w/w diethylene glycol monoethyl ether;
10.0% w/w CAPTEX 300 EP/NF;
15 10.0% PEG; and,
74.87% w/w water.

Example X

- 20 0.07% w/w travoprost free acid;
0.08% w/w cyclosporine A;
5.0% w/w diethylene glycol monoethyl ether;
10.0% w/w CAPTEX 300 EP/NF;
10.0% PEG; and,
25 74.87% w/w water.

Example XI

- 0.1% w/w bimatoprost
30 0.05% w/w cyclosporine A;
20% w/w 2-(2-Ethoxyethoxy)-Ethanol;

5% w/w propanediol;
3% w/w oleic acid; and,
71% w/w water.

5 Example XII

0.1% w/w latanoprost;
0.05% w/w cyclosporine A;
20% w/w 2-(2-Ethoxyethoxy)-Ethanol;
5% w/w propanediol;
10 3% w/w oleic acid; and
71% w/w water.

Example XIII

0.1% w/w latanoprost;
15 5.0% w/w minoxidil;
10% w/w 2-(2-Ethoxyethoxy)-Ethanol;
5% w/w propanediol;
3% w/w oleic acid; and
76.9% w/w water.

20

Example XIV

0.1% w/w latanoprost;
5.0% w/w minoxidil;
20% w/w 2-(2-Ethoxyethoxy)-Ethanol;
25 5% w/w propanediol;
3% w/w oleic acid; and,
66.9% w/w water.

Example XV

0.1% w/w latanoprost;

2.0% w/w minoxidil;

5 20% w/w 2-(2-Ethoxyethoxy)-Ethanol;

5% w/w propanediol;

3% w/w oleic acid; and,

69.9% w/w water.

10 Example XVI

0.1% w/w bimatoprost;

5.0% w/w minoxidil;

20% w/w 2-(2-Ethoxyethoxy)-Ethanol;

5% w/w propanediol;

15 3% w/w oleic acid; and,

66.9% w/w water.

Example XVII

0.1% w/w travoprost;

20 5.0% w/w minoxidil;

20% w/w 2-(2-Ethoxyethoxy)-Ethanol;

5% w/w propanediol;

3% w/w oleic acid; and,

66.9% w/w water.

25

Example XVIII

A 42-year old Caucasian man with alopecia areata applies the formulation of Example VIII twice a day to areas on his scalp where hair loss was evident, presenting as small patches of hair loss approximately the size of a quarter. After thirty days of application, the patient's hair will begin to grow on the patches.

5

Example XIX

A 32-year old male with androgenetic alopecia applies the formulation of Example VI to areas of hair loss on his scalp at least once a day. After forty-five days of continuous application, hair begins to regrow on the patient's scalp in the areas of hair loss.

10

Example XX

A 43-year old female suffering from telogen effluvium applies the formulation of Example IX to her scalp twice a day. After thirty-five days of daily application, hair begins to regrow on the patient's scalp in areas where the patient suffered hair loss.

15

Example XXI

A 53-year old male shaved the underside of his left and right forearm and applied the formulation of Ex. XI once each day to the left forearm but left the right forearm untreated. After 20 days, the hairs on the left forearm were more numerous, longer, darker and thicker as compared to the hairs on the right forearm which were less numerous, shorter, lighter and not as thick.

20

25

Example XXII

A 53-year old male shaved a four inch by two-inch area above his left and right knee and applied the formulation of Ex. XI to the shaved area above the left knee once a day and 5% minoxidil solution above the right knee once a day. After twenty days the hair growth in the area shaved above the left knee is slightly greater (more hair, longer hair) than in the area shaved above the right knee.

30

Claims:

1. A composition for use in the treatment of hair loss comprising about 0.05% – 0.1% w/w latanoprost or latanoprost acid and 0.05% - 0.1% cyclosporine A and 5.0% – 15.0% w/w diethylene glycol monoethyl ether.
2. The composition of claim 1 wherein the composition has about 0.1% w/w latanoprost or latanoprost acid and about 0.05% w/w cyclosporine A and at least 5% w/w diethylene glycol monoethyl ether.
3. The composition of claim 2 further comprising oleyl alcohol or ethanol.
4. The composition further comprising polyethylene glycol.
5. A composition for use in growing hair on a patient that experiencing hair loss comprising about 0.05% – 0.1% w/w latanoprost or latanoprost acid and 0.05% - 0.1% w/w cyclosporine A and 5.0% – 15.0% w/w CAPTEX 300 EP/NF.
6. The composition of claim 5 wherein composition comprises 0.06% w/w latanoprost acid and 0.08% w/w cyclosporine A.
7. The composition of claim 6 further comprising 10% w/w CAPTEX 300 EP/NF.
8. A composition for use in treating hair loss comprising about 0.05% – 0.1% w/w travoprost or travoprost acid and 0.05% - 0.1% w/w cyclosporine A.
9. The composition according to claim 8 further comprising one selected from the group consisting of diethylene glycol monoethyl ether, CAPTEX 300 EP/NF and polyethylene glycol.
10. The composition according to claims 1, 5 and 9 further comprising oleic acid.
11. A method of preventing hair loss on a patient comprising administering a formulation according to one of claims 1, 5 and 9 to a patient in need thereof.
12. The method of claim 11 wherein the formulation is applied once a day.
13. The method of claim 11 wherein the formulation is applied twice a day.
14. A method for causing hair growth in a patient suffering from hair loss comprising administering a formulation according to one of claims 1, 5 and 9 to a patient in need thereof.
15. The method of claim 14 wherein the patient experiences hair growth to a greater extent by applying the formulation of one of claims 1, 5 and 9 as compared to if the patient had not applied the formulation.

16. The method of claims 10 – 15 wherein the formulation maintains hair in anaphase longer than if the formulation had not been applied.
17. The method of claim 14 wherein the patient reverses a substantial amount of hair loss.
18. The method of claim 14 wherein the formulation comprises 0.06% w/w lanoaprost acid
5 and 0.08% w/w cyclosporine A and a pharmaceutically acceptable solvent and a penetration enhancer.
19. The method of growing hair wherein the formulation comprises 0.1% w/w travoprost or travoprost free acid and cyclosporine.
20. The method of claim 19 wherein the cyclosporine is cyclosporine A.
- 10 21. A composition for use in the treatment of hair loss or to grow hair comprising about 0.05% – 0.1% w/w latanoprost or latanoprost acid and 1.0% - 5.0% minoxidil or minoxidil sulphate.
22. The composition of claim 21 wherein the composition has about 0.1% w/w latanoprost or latanoprost acid and about 5.0% w/w minoxidil and at least 5% w/w diethylene glycol
15 monoethyl ether.
23. The composition of claim 21 further comprising oleyl alcohol or ethanol.
24. The composition of claim 21 further comprising polyethylene glycol.
25. A composition for use in the treatment of hair loss or to grow hair comprising about 0.05% – 0.1% w/w bimatoprost or bimatoprost acid and 1.0% - 5.0% minoxidil or
20 minoxidil sulphate.
26. The composition of claim 25 wherein the composition has about 0.1% w/w bimatoprost or bimatoprost acid and about 5.0% w/w minoxidil and at least 5% w/w diethylene glycol monoethyl ether.
27. The composition of claim 25 further comprising oleyl alcohol or ethanol.
- 25 28. The composition of claim 25 further comprising polyethylene glycol.
29. A composition for use in the treatment of hair loss or to grow hair comprising about 0.05% – 0.1% w/w travoprost or travoprost free acid and 1.0% - 5.0% minoxidil or minoxidil sulphate.
- 30 30. The composition of claim 29 wherein the composition has about 0.1% w/w travoprost or travoprost free acid and about 5.0% w/w minoxidil and at least 5% w/w diethylene glycol monoethyl ether.

31. The composition of claim 29 further comprising oleyl alcohol or ethanol.
32. The composition of claim 29 further comprising polyethylene glycol.

ABSTRACT

Compositions and methods for the treatment of hair growth and the prevention of hair loss.

5

10